Figure 5. Effect of phloroglucinol on EPC mobilization in LLC tumor-bearing mice.

(A) Schematic experimental schedule of in vivo EPC mobilization kinetics. After subcutaneous injection with 5×10⁶ LLC, the mice were orally administered DMSO vehicle (control) or 0.94 mg/kg phloroglucinol daily for 5 days after the initiation of therapy. Circulating MNCs were harvested at day 5 by Ficol-gradient centrifugation. (B) A subsequent gate was used to select the total CD45^NEG cell population. Corresponding flow cytometric analysis was used to detect CD34^POS cells in the gated CD45 ^NEG cell population. The EPC population was represented as CD45^NEG/CD34^POS cells. (C) Statistical difference between phloroglucinol after oral administration of both phloroglucinol and vehicle in LLC-tumor bearing mice. Bar graph represents marked differences in EPC frequency at day 5 after daily injection of phloroglucinol or vehicle (*P<0.05).